

**Amendments to the Claims**

Claim 1. (Currently amended) An allogeneic immunotherapeutic agent for the treatment of prostate cancer comprising three human prostate cell lines from three different sources, ~~of which one, two or three cell lines are derived from normal tissue(s), wherein each said normal tissue(s) is (are)~~ wherein at least one human prostate cell line is non-cancerous ~~from a source which is a non-cancerous prostate.~~

Claims 2-10. (Canceled).

Claim 11. (Previously amended) An allogeneic immunogenic composition comprising an immunotherapeutic agent of claim 1 combined with a vaccine adjuvant selected from the group consisting of BCG, *M. Vaccae*, Tetanus toxoid, Diphtheria toxoid, *Bordetella Pertussis*, interleukin 2, interleukin 12, interleukin 4, interleukin 7, Complete Freund's Adjuvant, Incomplete Freund's Adjuvant, and non-specific adjuvants.

Claim 12. (Previously amended) An immunogenic composition comprising an immunotherapeutic agent of claim 1 combined with a vaccine adjuvant, wherein the adjuvant is a mycobacterial preparation.

Claims 13-22. (Canceled).

Claim 23. (New) The allogeneic immunotherapeutic agent for the treatment of prostate cancer according to claim 1, wherein at least two of the human prostate cell lines are non-cancerous.

Claim 24. (New) The allogeneic immunotherapeutic agent for the treatment of prostate cancer according to claim 1, wherein all of the human prostate cell lines are non-cancerous.